Talis Biomedical Corporation
TLIS · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $15,363 | $15,487 | $13,559 | $10,496 |
| - Cash | $59,867 | $70,337 | $76,732 | $87,996 |
| + Debt | $18,800 | $19,241 | $19,668 | $20,083 |
| Enterprise Value | -$25,704 | -$35,609 | -$43,505 | -$57,417 |
| Revenue | $0 | $73 | $151 | $76 |
| % Growth | -100% | -51.7% | 98.7% | – |
| Gross Profit | -$84 | -$195 | -$471 | $70 |
| % Margin | – | -267.1% | -311.9% | 92.1% |
| EBITDA | -$9,494 | -$13,855 | -$14,289 | -$16,377 |
| % Margin | – | -18,979.5% | -9,462.9% | -21,548.7% |
| Net Income | -$8,849 | -$13,035 | -$13,460 | -$15,682 |
| % Margin | – | -17,856.2% | -8,913.9% | -20,634.2% |
| EPS Diluted | -4.86 | -7.15 | -7.4 | -8.62 |
| % Growth | 32% | 3.4% | 14.2% | – |
| Operating Cash Flow | -$11,330 | -$6,427 | -$11,357 | -$11,144 |
| Capital Expenditures | $0 | $0 | $93 | -$70 |
| Free Cash Flow | -$11,330 | -$6,427 | -$11,264 | -$11,214 |